AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product - Seite 2
There are approximately 90,000 patients in the U.S. with EPI caused by chronic pancreatitis according to the National Pancreas Foundation, and more than 30,000 patients with EPI caused by CF according to the Cystic Fibrosis Foundation. The current therapeutic standard of care for these patients are porcine pancreatic enzyme replacement therapy (PERT) pills.
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a biopharmaceutical company engaged in the research and development of non-systemic biologics for the
treatment of patients with gastrointestinal disorders. The Company is headquartered in New York, NY, with scientific operations based in Langlade, France and clinical operations in Hayward,
California. Additional information on the Company can be found at www.azurrx.com.
About Delpharm
Delpharm is a European leader in contract manufacturing and development of medicines for pharmaceutical companies, generating €750m turnover and is wholly
owned by its management. Delpharm operates 17 manufacturing plants across Europe and Canada providing the majority of dosage forms available on the market, clinical batches manufacturing for Phases
1-3, and full development services. Additional information on Delpharm can be found at www.delpharm.com.
Lesen Sie auch
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not
historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is
possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking
statements. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results, including those related
to the clinical development of MS1819 and the results of its clinical trials, are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the
heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.